• Home
  • Study Details
Coming Soon

Personalized vaccine with pembrolizumab for patients with non-small cell lung cancer or squamous cell cancer of the head and neck

In this study, we want to learn more about the safety and effectiveness of using a personalized vaccine with a drug called pembrolizumab for the treatment of non‐small cell lung cancer (NSCLC) and squamous cell cancer of the head and neck (SCCHN).

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Jared Weiss
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck, Lung)

IRB Number

18-3302

ClinicalTrials.gov

NCT04266730

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research